Prateek Khanna, M.B., B.S.

Hometown: Delhi, India
Profiles: Google Scholar

Prateek completed his medical school from University of Delhi, India and earned his MBBS (MD equivalent) degree in 2014. He joined Beth Israel Deaconess Medical Center in 2014 as a postdoctoral fellow in Dr. Rupal Bhatt's lab to work on elucidating mechanisms of resistance to VEGFR-TKI therapy in clear cell renal cell carcinoma. He completed his residency in internal medicine at Mount Auburn Hospital, Cambridge in 2021 and fellowship in geriatric medicine at NYU Grossman School of Medicine in 2022. Prateek completed his fellowship in Hematology/Oncology at DFCI Brighton at St. Elizabeth's Medical Center in July 2025 and is currently an attending physician in the Lank Center for GU Oncology at DFCI. 

Selected Publications:

• ​Khanna P, Soh HJ, Chen CH, Saxena R, Amin S, Naughton M, Joslin PN, Moore A, Bakouny Z, O'Callaghan C, Catalano P, Signoretti S, McKay R, Choueiri TK, Bhasin M, Walther T, Bhatt RS. ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma. Sci Transl Med. 2021 Jan 20;13(577):eabc0170. doi: 10.1126/scitranslmed.abc0170. PMID: 33472951.